JP2009528997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528997A5 JP2009528997A5 JP2008556356A JP2008556356A JP2009528997A5 JP 2009528997 A5 JP2009528997 A5 JP 2009528997A5 JP 2008556356 A JP2008556356 A JP 2008556356A JP 2008556356 A JP2008556356 A JP 2008556356A JP 2009528997 A5 JP2009528997 A5 JP 2009528997A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- polymorphs
- stereoisomers
- hydrates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 20
- 150000004677 hydrates Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 239000000463 material Substances 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 210000002381 plasma Anatomy 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 150000002500 ions Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- VBCIBLUDWOQXTK-UHFFFAOYSA-N 2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 VBCIBLUDWOQXTK-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- -1 cyano, formyl Chemical group 0.000 claims 2
- KRCXWINWQAFOKB-UHFFFAOYSA-L disodium 2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]acetate Chemical compound [Na+].[Na+].[O-]C(=O)Cc1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1.[O-]C(=O)Cc1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1 KRCXWINWQAFOKB-UHFFFAOYSA-L 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- MEJBANGHCJDFPZ-UHFFFAOYSA-N 2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1C=C1C(=O)NC(=O)S1 MEJBANGHCJDFPZ-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/359,657 US7781464B2 (en) | 2003-01-17 | 2006-02-21 | Heterocyclic diphenyl ethers |
| US11/359,657 | 2006-02-21 | ||
| PCT/US2007/004007 WO2007097992A2 (en) | 2006-02-21 | 2007-02-15 | Novel heterocyclic diphenyl ethers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009528997A JP2009528997A (ja) | 2009-08-13 |
| JP2009528997A5 true JP2009528997A5 (https=) | 2013-03-07 |
| JP5414280B2 JP5414280B2 (ja) | 2014-02-12 |
Family
ID=38437869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008556356A Expired - Fee Related JP5414280B2 (ja) | 2006-02-21 | 2007-02-15 | 新規複素環式ジフェニルエーテル |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7781464B2 (https=) |
| EP (1) | EP2004185B1 (https=) |
| JP (1) | JP5414280B2 (https=) |
| CA (1) | CA2642650C (https=) |
| ES (1) | ES2427726T3 (https=) |
| PL (1) | PL2004185T3 (https=) |
| TW (1) | TWI394748B (https=) |
| WO (1) | WO2007097992A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| US20090203744A1 (en) * | 2005-07-29 | 2009-08-13 | Pande Y Surendrakumar Satyanarayan | Novel pyridine derivatives |
| NZ579372A (en) * | 2007-03-07 | 2012-02-24 | Janssen Pharmaceutica Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| JPWO2009025170A1 (ja) * | 2007-08-23 | 2010-11-25 | コニカミノルタオプト株式会社 | 長尺の位相差フィルム、長尺の楕円偏光フィルム、楕円偏光板、及び画像表示装置 |
| WO2009143041A1 (en) | 2008-05-20 | 2009-11-26 | Merck & Co., Inc. | Efficient production of heterologous proteins using mannosyl transferase inhibitors |
| CN103108634B (zh) | 2010-07-28 | 2015-08-12 | 幽兰化学医药有限公司 | 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物 |
| US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
| US12151372B2 (en) | 2019-02-27 | 2024-11-26 | Berkshire Grey Operating Company, Inc. | Systems and methods for hose routing in programmable motion systems |
| EP3959050B1 (en) | 2019-04-25 | 2024-04-17 | Berkshire Grey Operating Company, Inc. | System and method for maintaining vacuum hose life in hose routing systems in programmable motion systems |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020049240A1 (en) | 1994-12-19 | 2002-04-25 | Beecham Group P.1.C. | Novel compounds |
| US5166137A (en) | 1991-03-27 | 1992-11-24 | Nobipols Forskningsstiftelse | Guluronic acid polymers and use of same for inhibition of cytokine production |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| TW268952B (https=) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| US5527546A (en) | 1994-08-10 | 1996-06-18 | Bayer Corporation | Human interleukin 6 inhibitor |
| ATE271128T1 (de) | 1995-05-11 | 2004-07-15 | Applied Research Systems | Inhibitoren der il-6 aktivitaet |
| TW577875B (en) | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
| JP2002511852A (ja) * | 1997-05-07 | 2002-04-16 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体 |
| WO1999024415A1 (en) * | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
| US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US7105552B2 (en) * | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US6699896B1 (en) | 1998-05-12 | 2004-03-02 | Wyeth | Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| WO1999064417A2 (en) | 1998-06-05 | 1999-12-16 | Astrazeneca Ab | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
| WO2000000194A1 (en) | 1998-06-27 | 2000-01-06 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
| US6664281B1 (en) | 1998-08-27 | 2003-12-16 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| AU757729B2 (en) | 1999-04-07 | 2003-03-06 | Sankyo Company Limited | Amine derivatives |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| TWI284533B (en) | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
| JP2001072592A (ja) * | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| KR20010099634A (ko) | 1999-07-01 | 2001-11-09 | 할리 켈빈 비. | 텔로머라제 저해제 및 그 사용 방법 |
| SE514748C2 (sv) * | 1999-08-03 | 2001-04-09 | Sahlin Gjutteknik Ab | Spolsten |
| CN1155586C (zh) | 1999-08-23 | 2004-06-30 | 杏林制药株式会社 | 取代的苄基噻唑烷-2,4-二酮衍生物 |
| JP2003508391A (ja) | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| JP2001199888A (ja) | 2000-01-24 | 2001-07-24 | Fujimoto Brothers:Kk | 糖尿病治療剤 |
| JP2001308814A (ja) | 2000-04-19 | 2001-11-02 | Hitachi Ltd | フレーム構成自動識別通信装置 |
| EP1148054B1 (en) | 2000-04-21 | 2005-11-23 | Pfizer Products Inc. | Thyroid receptor ligands |
| US6620830B2 (en) | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
| US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| CA2460541A1 (en) | 2001-09-14 | 2003-04-03 | Helle Birk Olsen | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer |
| US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| JP2007523842A (ja) | 2003-03-11 | 2007-08-23 | ノボ ノルディスク アクティーゼルスカブ | 酸安定化されたインスリンを含有する薬学的製剤 |
| US7087576B2 (en) | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| EP1858845A2 (en) * | 2005-03-18 | 2007-11-28 | Orchid Chemicals and Pharmaceuticals Limited | Novel tyrosine derivatives |
-
2006
- 2006-02-21 US US11/359,657 patent/US7781464B2/en not_active Expired - Fee Related
-
2007
- 2007-02-15 WO PCT/US2007/004007 patent/WO2007097992A2/en not_active Ceased
- 2007-02-15 ES ES07750819T patent/ES2427726T3/es active Active
- 2007-02-15 EP EP07750819.0A patent/EP2004185B1/en not_active Not-in-force
- 2007-02-15 JP JP2008556356A patent/JP5414280B2/ja not_active Expired - Fee Related
- 2007-02-15 CA CA2642650A patent/CA2642650C/en not_active Expired - Fee Related
- 2007-02-15 PL PL07750819T patent/PL2004185T3/pl unknown
- 2007-02-26 TW TW096106502A patent/TWI394748B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528997A5 (https=) | ||
| TWI519515B (zh) | Ｂ型肝炎抗病毒劑 | |
| JP2019069941A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP7710215B2 (ja) | ピロール化合物 | |
| JP6371312B2 (ja) | 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物 | |
| TW201720820A (zh) | B型肝炎核心蛋白質調節劑 | |
| CN101360743A (zh) | 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物 | |
| TW200539854A (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| JP2008513499A5 (https=) | ||
| JP2017502976A (ja) | １，２ナフトキノン誘導体及びその製造方法 | |
| WO2011150457A2 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors | |
| JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JP2008530242A5 (https=) | ||
| CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
| JP4832897B2 (ja) | エステル誘導体及びその医薬用途 | |
| KR20070045272A (ko) | 2-페닐피리딘 유도체 | |
| JP6903266B2 (ja) | １，２ナフトキノン誘導体及びその製造方法 | |
| KR20180002698A (ko) | 2-｛4-[2-(｛[2-(4-클로로페닐)-1,3-티아졸-4-일]메틸｝설파닐)-3,5-디시아노-6-(피롤리딘-1-일)피리딘-4-일]페녹시｝에틸-ｌ-알라닐 ｌ-알라니네이트 모노하이드로클로라이드의 제조방법 | |
| JP2025531344A (ja) | ２ｈ－ベンゾトリアゾール誘導体、その調製方法及びそれを含有する医薬組成物 | |
| US10532987B2 (en) | Compounds and methods for inducing browning of white adipose tissue | |
| JP2013532682A5 (https=) | ||
| JPH01242574A (ja) | 含窒素縮合環を有するピペリジン及びピペラジン誘導体、その製造方法並びにそれを含む薬学的組成物 | |
| JPWO2007004733A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JP6799692B2 (ja) | アセトフェノン系化合物、その調製方法及び脂肪肝の予防・治療への使用 | |
| JP2007519706A (ja) | Ｈｉｖプロテアーゼ阻害剤及びシトクロームｐ４５０酵素活性阻害剤を含んでなる組成物 |